Biogen weighs layoffs amid bleak Aduhelm launch, STAT reports

Biogen is considering cost-cutting measures, including layoffs, as the launch of its Alzheimer's disease treatment Aduhelm is "far bleaker than what it has publicly disclosed," Damian Garde and Adam Feuerstein report, citing a person with knowledge of the situation. Just over 100 Alzheimer's patients had been infused with Aduhelm as of September 11, Garde and Feuerstein say. While the number is rising slowly, it is drastically below both Biogen's internal projections and Wall Street's expectation that thousands would be using the drug by now, they add. Shares of Biogen are down 4% to $248.99 in premarket trading following the report. Reference Link